"Analysis of the Primary Presenting Symptoms and Hematological Findings of COVID19 Patients in Bangladesh"

Abu Taiub Mohammed Mohiuddin Chowdhury
Xi’an Jiaotong University Medical College First Affiliated Hospital

Md Rezaul Karim
Hubei University of Medicine

H.M. Hamidullah Mehedi
Chattogram General Hospital

Mohammad Shahbaz
Chakoria Upazilla Health Complex

Md Wazed Chowdhury
Office of the Civil Surgeon Chattogram

Dan Guo
Xi’an Jiaotong University Medical College First affiliated Hospital

Shuixiang He (✉ dyyyyjxk@xjtu.edu.cn)
Xi’an Jiaotong University Medical College First Affiliated Hospital

Research article

Keywords: SARS-CoV-2, COVID-19, real-time RT-PCR, COVID-19 symptoms, COVID19 hematological findings, Bangladesh

DOI: https://doi.org/10.21203/rs.3.rs-35016/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License.
Read Full License
Abstract

Background:

SARS-CoV-2 infection or COVID-19 is a global pandemic. From the time of identification to till, multiple clinical symptoms and parameters have been identified by the researchers of various countries and regions regarding the diagnosis and presentations of COVID19 disease. In this manuscript, we investigated the primary symptoms and basic hematological presentations of SARS-CoV-2 infection among the Bangladeshi patients.

Methodology: We have collected the disease history of mild to moderate degree of COVID19 patients; hematological and biochemical on admission reports of moderate degree COVID19 patients. All of them were tested positive for SARS-CoV-2 by RT PCR in different institutes in Bangladesh.

Results: According to this study though COVID19 patients in Bangladesh commonly presented with fever, cough, fatigue, shortness of breath, and sore throat, but symptoms like myalgia, diarrhea, skin rash, headache, Abdominal pain/cramp, nausea, vomiting, restlessness, and a higher temperature of >100°F have a greater presentation rate and more frequent than other published studies. CRP and Prothrombin time was found to increase in all the patients. Serum ferritin, ESR, SGPT, and D-Dimer were found increased among 53.85%, 80.43, 44%, and 25% patients respectively. 17.39% of the patients had leucocytosis and neutrophilia. 28.26% of patients presented with lymphocytopenia. 62.52% of patients had mild erythrocytopenia.

Conclusion: Despite some similarities, our study has evaluated a different expression in presenting symptoms in the case of COVID19 patients in Bangladesh. CRP, Prothrombin time, serum ferritin, ESR, SGPT, D-Dimer, erythrocytopenia, and lymphocytopenia can be initial diagnostic hematological findings and assessments for prognosis COVID19 disease. Also, Gender variation has a different scenario of clinical and laboratory appearance in this region.

Background:

SARS-CoV-2 infection or COVID-19 is a current global pandemic. This is a single-stranded RNA virus originated from the beta Coronavirus family. [1] The rapid spread of SARS-CoV-2 has led to the declaration of a global pandemic barely three months after emerging [2]. The disease was first notified in December 2019 in the Hubei province of the Republic of China as a cluster of 27 cases of pneumonia of an unknown cause. [3] All these patients presented with Radiological findings like glassy lung opacity along with clinical presentations like fever, dyspnoea, and dry cough. From the time of identification to till, multiple clinical symptoms and parameters have been identified by the researchers of various countries and regions regarding the diagnosis and presentations of COVID19 disease. In this manuscript, we investigated the primary symptoms and hematological presentations of SARS-CoV-2 infection among Bangladeshi patients.
Methodology:

For the analysis of the presenting symptoms of SARS-CoV-2 infection, we collected the data of COVID19 patients from Chattagram Civil Surgeon's office, and the Chakoria Upazila Health and Family Welfare Officer's (UH&FPO) office. All the patients were tested positive for SARS-CoV-2 by RT PCR at Bangladesh Institute of Tropical and Infectious Disease (BITID) and Cox's Bazar Medical College Hospital and were treated (either as an outpatient or as inpatient with mild to moderate degree of illness) under different COVID19 dedicated hospitals in Chattagram district, and Chokoria Upazila Health complex. A total of 638 patient's data that were tested positive from May 5th to June 5th, 2020 were collected. Each of the patients was individually interviewed to find out the details of the disease symptoms, history, comorbid condition, and associated complaints.

Patients with severe comorbid conditions like severe Bronchial asthma, COPD exacerbation, severe ischemic heart disease, severe uncontrolled diabetes mellitus, advanced renal and hepatic disease, patients with carcinoma, hospitalized and Immuno-compromised patients were not included in this study. Due to misconception and unreliable statement 127 patient's data were discarded. 138 patients had comorbid conditions that affected the presenting symptoms or had existing symptoms from before, so these were also excluded. 53 patients did not respond to our call or unwilling to participate in the study. Following exclusion for symptomatic analysis 320 patients of 13 to 56 years (mean age 35.81 years) of age were included in this study.

To evaluate the hematological changes in the patients we gathered the hematological and biochemical on admission reports of 89 admitted patients (moderate degree COVID19 disease) from May 5th to June 5th, 2020. This included Hemoglobin level, Erythrocyte Sedimentation rate, total and differential count of WBC, RBC, Platelet, C-Reactive Protein (CRP), SGPT, Serum Ferritin, Prothrombin time, D-Dimer, and Serum creatinine. According to the clinical presentation patients with fever were tested for Dengue NS1 antigen, Dengue IgG & IgM antibody, Salmonella Typhi IgM and IgG antibody, ICT for malaria (Antigen for Plasmodium Falciparum, Vivax, Malaria, and Ovale) and Widal test to exclude Dengue, Malaria, and Enteric fever. Patients who had a chronic comorbid condition and any recent history of hematological, biochemical abnormalities, or chest radiograph abnormality within a period of 30 days were not included in this study. In our observation, all patients with severe diseases had pre-existing comorbid conditions. Therefore only the laboratory findings of patients with moderate COVID19 disease were collected. Following exclusion criteria (others as described earlier) 39 patients were excluded from the study. A total of 50 patient's data were included in the analysis. Male 37 males and 13 females of 31 to 59 years of age (mean 42.8 years).

Informed consent was obtained in every case. Ethical committee approval was obtained from Xi’an Jiaotong University. Statistical analysis was done by Graphpad Prism software. T-test was done to see the difference in the values. A P value of < 0.05 was considered significant.

Results:
Table 1: A total of 320 patients were included in the study. The patient’s ages were 13 to 56 years. 208 (65%) were male and 112 (35%) were female. [Figure 1A] The Mean age of the patients was 35.81 ± 11.68 years. The mean age of male and female patients was 34.16 ± 11.08 years and 38.89 ± 12.19 years respectively. [Figure 1B] 129 (40.31%) patients were under hospital and 191 (59.69%) were under home isolation. Out of 320 patients, 262 (81.88%) were symptomatic and 58 (18.13%) were asymptomatic. The age of male and female symptomatic patients was 34.15 ± 11.07 years and 38.89 ± 12.19 years. The duration of symptoms was 5.66 ± 3.60 days in general. In the case of male patients, this was 5.72 ± 3.50 days and female was 5.56 ± 4.0 days. [Figure 1C]

| Parameters                              | Number       |
|-----------------------------------------|--------------|
| Number of Patients                      | 320          |
| Male                                    | 208 (65%)    |
| Female                                  | 112 (35%)    |
| Age (mean ± SD)                         | 35.81 ± 11.07|
| Age of Male patients (mean ± SD)        | 34.15 ± 11.07|
| Age of Female patients (mean ± SD)      | 38.89 ± 12.19|
| Asymptomatic                            | 58 (18.12%)  |
| symptomatic                             | 262 (81.88%) |
| Hospitalized                            | 129 (40.31%) |
| Home isolation                          | 191 (59.69%) |
| Duration of symptoms (days ± SD)        | 5.66 ± 3.60  |
| Male, Duration of symptoms (days ± SD)  | 5.72 ± 3.50  |
| Female, Duration of symptoms (days ± SD)| 5.56 ± 4.0   |
| Body temperature < 100° F               | 68 (30.90%)  |
| Body temperature > 100° F               | 152 (69.09%) |
| Comorbid condition (n)                  | 152 (47.50%) |

Sub-group analysis of hospital/home isolated patients hospitalized patients 107 (82.3%) were male, 23 (17.82%) were female; in the case of home isolation 141 (71.57%) were male and 50 (26.18%) were female. [Figure 1D] T-test was not significant among the groups. Age group was as following 10 to 20 years 30 patients, 21 to 30 years 53 patients, 31 to 40 years 127 patients, 41 to 50 years 71 patients, and 51 to 60 years 39 patients. [Figure 1E]
Among all the patients, highest 220 (68.8%) patient presented with fever, weakness 134 (41.9%), cough 126 (57.3%), anorexia 117 (36.6%), mayalgia 112 (35.0%), diarrhea 98 (30.6%), nausea 94 (29.4%), chest tightness 93 (42.3%), sleep disturbance 83 (25.9%), headache 75 (23.4%), sore throat 63 (19.7%), respiratory distress 61 (19.1%), rhinorrhoea 53 (16.6%), abdominal crump/ pain 53 (16.6%), small localize rash on the body (with or without itching) 47 (14.7%), vomiting 29 (9.1%), and vertigo 11 (3.4%). [Figure 2 A & B]

The maximum temperature was found 104°F. 220 patients had a history of fever and 100 patients had no fever history. [Figure 2D] Out of 220 patients presented with fever, 68 patients had temperatures < 100°F and 152 presented with > 100°F temp. [Table 1] Febrile patients had a history of a minimum of 2 days and a maximum 14 days with a mean of 6.09 ± 3.69 days of fever history. Patients with < 100°F temperature had a history of 5.72 ± 5.13 days (2 to 14 days) and patients with > 100°F temperature had a history of 5.73 ± 2.47 days (2 to 10 days) of febrile history. [Figure1F] Among 126 patients with a history of cough 103 (81.75%) experienced dry cough and 23 (18%) complained of sputum with cough; among them, males were 93(73%) and female were 34 (26.95%). [Figure 2E] Patients had 5.67 ± 3.60 days (2–14 days) of history of symptoms in general. Male patients have 5.72 ± 3.5 days (2–13 days) and females had 5.56 ± 4.0 days (2–14 days) of the history of symptoms. These figures are not significant in the t-test, P = 0.998. Among the hospitalized patients 107 were male patients of 37 ± 10.95 years (22 to 54 years), 48 were female of 36.88 ± 8.13 years (22 to 50 years). In the case of home isolation, this was 34.16 ± 10.93 years (17 to 54 years) in males and 39.82 ± 9.84 (24 to 56 years) in females. [Figure 2F]

Table 2: Subgroup analysis of patients according to the symptoms. Fever was presented by 220 patients, among this male were 157 (71.36%) and females were 63 (28.64%); this is 95.73% and 64.29% against total symptomatic male and female patients. Weakness was presented by 134 patients, male 98 (73.13%), and female 36 (26.87%); this is 59.76% and 36.73% against total symptomatic male and female patients. The cough was presented by 126 patients male 92 (73.01%) and female 34 (26.87%); this is 56.10% and 34.69% against total symptomatic male and female patients. Anorexia was presented by 117 patients, male 81 (69.23%), and female 36 (30.77%); this is 49.39% and 36.73% against total symptomatic male and female patients. Generalized mayalgia was presented by 122 patients, male 87 (77.68%), and female 25 (22.32%); this is 53.05% and 25.51% against total symptomatic male and female patients. Diarrhoea was presented by 94 patients, male 61 (62.24%), and female 25 (26.60%); this is 37.20% and 37.76% against total symptomatic male and female patients. Nausea was presented by 98 patients, male 61 (62.24%), and female 37 (37.76%); this is 42.07% and 25.51% against total symptomatic male and female patients. Chest tightness was presented by 93 patients, male 52 (55.91%), and female 41 (44.08%); this is 31.71% and 41.84% against total symptomatic male and female patients. Sleep disturbance was presented by 83 patients, male 51 (61.44%), and female 32 (38.55%); this is 31.10% and 32.65% against total symptomatic male and female patients. Headache was presented by 75 patients, male 58 (77.33%), and female 17 (22.67%); this is 35.37% and 17.35% against total symptomatic male and female patients. Sore throat was presented by 63 patients, male 30 (47.61%), and female 33 (52.38%); this is 18.29% and 33.67% against total symptomatic male and female patients. Breathing difficulty was presented by 61
patients, male 43(70.49%), and female 18(29.51%); this is 26.22% and 18.37% against total symptomatic male and female patients. Rhinorrhea was presented by 53 patients, male 30(56.60%), and female 23(43.31%); this is 18.29% and 23.47% against total symptomatic male and female patients. Abdominal cramp/pain was presented by 53 patients, male 27(50.94%), and female 28(52.83%); this is 16.46% and 28.57% against total symptomatic male and female patients. Skin rash was presented by 47 patients, male 18(38.30%), and female 29(61.70%); this is 10.98% and 29.59% against total symptomatic male and female patients. Vomiting was presented by 29 patients, male 22(75.86%), and female 7(24.13%); this is 13.41% and 7.14% against total symptomatic male and female patients. Vertigo was presented by 11 patients, male 3(27.27%), and female 8(72.73%); this is 1.83% and 8.16% against total symptomatic male and female patients. Restlessness was presented by 82 patients, male 57(69.51%), and female 25(30.49%); this is 34.76% and 25.51% against total symptomatic male and female patients. [Figure 3 A & B]
Table 2
Symptomatic presentation according to gender variation. The total number of patients n = 320.

| Symptoms                  | No. of Patients | Male       | Female      | % Against male Symptomatic Patients, n = 164 | % Against female Symptomatic Patients, n = 98 |
|---------------------------|-----------------|------------|-------------|---------------------------------------------|------------------------------------------|
| Fever                     | 220             | 157 (71.36%) | 63 (28.64%) | 95.73%                                       | 64.29%                                   |
| Weakness                  | 134             | 98 (73.13%)  | 36 (26.87%) | 59.76%                                       | 36.73%                                   |
| Cough                     | 126             | 92 (73.01%)  | 34 (26.87%) | 56.10%                                       | 34.69%                                   |
| Anorexia                  | 117             | 81 (69.23%)  | 36 (30.77%) | 49.39%                                       | 36.73%                                   |
| Mayalgia                  | 112             | 87 (77.68%)  | 25 (22.32%) | 53.05%                                       | 25.51%                                   |
| Diarrhoea                 | 98              | 61 (62.24%)  | 37 (37.76%) | 37.20%                                       | 37.76%                                   |
| Nausea                    | 94              | 69 (73.40%)  | 25 (26.60%) | 42.07%                                       | 25.51%                                   |
| Chest tightness           | 93              | 52 (55.91%)  | 41 (44.08%) | 31.71%                                       | 41.84%                                   |
| Sleep disturbance         | 83              | 51 (61.44%)  | 32 (38.55%) | 31.10%                                       | 32.65%                                   |
| Headache                  | 75              | 58 (77.33%)  | 17 (22.67%) | 35.37%                                       | 17.35%                                   |
| Sore throat               | 63              | 30 (47.61%)  | 33 (52.38%) | 18.29%                                       | 33.67%                                   |
| Breathing difficulty      | 61              | 43 (70.49%)  | 18 (29.51%) | 26.22%                                       | 18.37%                                   |
| Rhinorrhea                | 53              | 30 (56.60%)  | 23 (43.31%) | 18.29%                                       | 23.47%                                   |
| Abdominal crump/pain      | 53              | 27 (50.94%)  | 28 (52.83%) | 16.46%                                       | 28.57%                                   |
| Skin rash                 | 47              | 18 (38.30%)  | 29 (61.70%) | 10.98%                                       | 29.59%                                   |
| Vomiting                  | 29              | 22 (75.86%)  | 7 (24.13%)  | 13.41%                                       | 7.14%                                    |
| Vertigo                   | 11              | 3 (27.27%)   | 8 (72.73%)  | 1.83%                                        | 8.16%                                    |
| Restless                  | 82(25.63%)      | 57 (69.51%)  | 25 (30.49%) | 34.76%                                       | 25.51%                                   |

Table 3: 152 (47.50%) patients have a comorbid condition. 47 (30.92%) had T2 DM, 64 (42%) had HTN, 23 (15.13%) had bronchial asthma, 17 (11.2%) had ischemic heart disease, 13 (8.55%) has sinusitis, 20 (13.16%) had other manifestations like a fungal infection, hypothyroid, hepatitis B (+)ve, etc. 42 (13.13%) had DM and HTN and 9 (2.81%) had DM-HTN-Ischemic Heart Disease.
Table 3
Comorbid conditions n = 152

| Name of disease             | Number of patients and % |
|-----------------------------|--------------------------|
| T2DM                        | 47 (30.92%)              |
| HTN                         | 64 (42%)                 |
| IHD                         | 17 (11.2%)               |
| Sinusitis                   | 13 (8.55%)               |
| Bronchial Asthma            | 23 (15.13%)              |
| HBV (+) Ve                  | 10 (6.58%)               |
| H/O Pulmonary TB            | 7 (4.61%)                |
| T2DM and HTN                | 42 (13.13%)              |
| T2DM, HTN, and IHD          | 9 (2.81%)                |
| Others (Skin allergy, Migraine, Thyroid disease, etc) | 20 (13.16%) |

Table 4: Hematological findings, numbers of patients were n = 50. Male 37 male and 13 female, mean age was 42.8 ± 8.268 (31 to 59 years). Routine blood count was done on 46 patients, findings with ranges were as following: Hemoglobin 13.42 ± 1.324 gm/dL (11.5 to 16.3 gm/dL); ESR 29.52 ± 18.46 mm in 1st hour (4 to 46 mm in 1st hour), WBC 6851 ± 2721 (4300 to 16000/CC), RBC 4.94 ± 0.65 Million/CC (3.75 to 5.94 Million/CC); Platelet 229804 ± 68932 /CC (160000–421000/CC), Neutrophil 65.43 ± 12.11% (48 to 85%); Lymphocyte 28.72 ± 11.97% (20 to 45%), Monocyte 3.89 ± 2.42% (2 to 10%), Esinophil 1.96 ± 1.26% (0 to 5%), Basophil 0.065 ± 0.24% (0 to 1%). CRP 16.65 ± 18.81 mg/dl (0.95 to 60.2 mg/dl, number of patients 43); SGPT 72.04 ± 49.56 Unit/L (22 to 181, number of patients 25); Serum Ferritin 659.9 ± 488.9 ng/ml (169 to 1550, number of patients 26); Prothombin Time 14.35 ± 0.95 seconds (13.6 to 15.7 seconds, number of patients 10); D-Dimer 0.25 ± 0.28 µgm/ml (0.025–0.68 µgm/ml, number of patients 12), Serum Creatinine 1.08 ± 0.17 mg/dl (0.89 to 1.3 mg/dl, number of patients 12).
Subgroup analysis of the laboratory routine hematological findings based on patients gender variations are as follows: Hemoglobin level was deceased among 71.42% male and 36.36% female; ESR was increased in 80% male and 72.73% female; Leucocytosis was found in 17.14% male and 18.2% female; Neutrophilic leucocytosis was detected in 17.14% male and 18.2% female; Lymphocytopenia was found
among 31.43% male and 18.18% female; Reduce RBC level was noted in 27.27% female this was normal in all male patients. [Figure 3D]

Subgroup analysis of patients biochemical evaluation depending on patients gender: CRP and Prothrombin time (PT) was increased in all the male and female patients; increased SGPT level was found among 52.94% male and 25% female; increased serum ferritin level was seen among 68.75% male and 37.5% female; 18.8% male and 100% of female (1 of 1 female patient) had an increased level of serum D-Dimer. [Figure 3F] Difference between the decrease hemoglobin level (P = 0.0243) and increased SGPT (P = 0.0108) against male and female in the Chisquare test and t-test patients were found significant, others are not. [Figure 3G]

Discussion:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing COVID-19 has rapidly evolved as an epidemic outbreak and infected more than six and a half million individuals all over the world. Besides this, billions of others are directly affected by the citizens are affected by measures of social distancing and the socio-economic impact. COVID19 is a systemic infection causing a significant impact on the hematopoietic system and hemostasis mechanism. [3] The incubation period of this virus can be up to 14 days following exposure. According to the center for disease control and prevention (CDC), the individuals with COVID-19 have had a wide range of symptoms reported ranging from mild to severe illness. These symptoms may appear from the second day till the incubation period. These symptoms may include but not limited to cough, fever, chills, muscle pain, the heaviness of chest, shortness of breath or difficulty breathing, sore throat, and loss of taste or smell. Warning signs of COVID-19 include breathing difficulty, persistent pain or pressure in the chest, inability to wake or stay awake, sings of central cyanoses like bluish lips or face, and confusion. [4] Multiple studies have reported presenting symptoms of COVID-19 worldwide among which several symptoms are common, but due to geographical locations, these symptoms may differ.

In this study, we analyzed the COVID-19 cases in multiple centers in Bangladesh to assess these symptomatic and hematological variations from the rest of the world. Following exclusion, our study revealed that the primary presenting symptoms of 320 COVID19 patients in treated in multiple centers in Bangladesh include fever, cough, chest tightness, weakness, anorexia, myalgia, diarrhea, nausea, sleep disturbance, headache, sore throat, respiratory distress, rhinorrhea, abdominal pain, rash or skin lesion, vomiting, vertigo, and restlessness. Among these primary presenting symptoms, fever and cough were most common, and vomiting and vertigo were relatively uncommon. Chest tightness and weakness were relatively common in COVID-19 cases but not as much as fever and cough, which was present in the maximum number of cases affected by SARS-CoV-2 [Figure 2 A & B]. This study can help healthcare professionals in Bangladesh and others to narrow down the suspected COVID-19 affected cases and perform testing accordingly. In Bangladesh, unlike developed countries, real-time reverse transcription-polymerase chain reaction (RT-PCR) is the only available test which is recommended by the Institute of Epidemiology, Disease Control and Research (IEDCR) for the healthcare settings. The real-time RT-PCR is
of the high value of interest for the detection of COVID-19 disease due to its simplicity and specificity. [5–7] But unfortunately RT-PCR test has the risk of eliciting false-negative and false-positive results, as the sensitivity and specificity of the RT-PCR test are not 100%. [8] However, a chest computed tomography (CT) was reported 98% and 97% sensitive in two different studies. [9, 10]

One of the early studies regarding clinical characteristics of COVID-19 done on 1099 patients in China revealed that the most common symptoms were fever, cough, and fatigue which resembles findings of our study (68.8%, 57.3%, and 41.9%). [Figure 2 A & B] A study on the systematic review focusing on upper airway symptoms revealed that the common symptoms of COVID-19 were fever, cough, and fatigue. [11] These studies with our study confirm that fever and cough are the two most common onset symptoms of COVID-19, including in Bangladesh. Diarrhoea, on the other hand, was uncommon (3.8%) [12] Which is not uncommon in COVID-19 cases analyzed in our study, 30.6%. Symptoms like Hemoptysis (0.9% Vs 0%) and breathing difficulty (18.7% Vs 19.1%) show similarity with our findings. But Sore throat 13.9% Vs 19.7%; Headache 13.6% Vs 23.4%; Nausea & Vomiting 5% Vs 29% & and 9.1%; Myalgia 14.9% Vs 35% and Skin rash 0.2% Vs 14.7% has revealed a very different trends of presenting symptoms then the other reported studies. Our findings of Diarrhoea (30.6%) are similar to Song et al. This study reported SARS-CoV-2 induced diarrhoea could be the onset symptom in patients with COVID-19. [13] Up to 30% of patients with the Middle East respiratory syndrome (MERS) and 10.6% of patients with SARS had diarrhoea as the onset symptom. [14] Bao et al. revealed that vomiting is also associated as the onset symptom in some cases of COVID-19, [15] which was also present in the COVID-19 cases found in our study (9.1%). A similar result was also found in the case of rash/skin lesion in this study, which resembles a case study where a young male with full-body rash was a presenting symptom of COVID-19. [16] 16.6% of the patients in our study complained of mild to moderate amounts of abdominal cramp or pain. This finding also similar to a case study reported earlier that the acute abdomen was the early symptom of COVID-19. [17] During the data collection we have noticed 2 severe cases of COVID-19 with hemoptysis. As all the severe cases had per existing comorbid conditions, so were not included in his study. We have also observed three cases presented only with anorexia and two cases of severe myalgia later were diagnosed as SARS-CoV-2 infection. As an additional finding, restlessness was complained by 85 (25.63%) of patients this was 34.76% of symptomatic males and 25.51% of the symptomatic females [Table 2]. Based on our study findings minimally symptomatic patients or symptoms like abdominal cramp or pain, Myalgia, localize skin lesion or rash, sleep disturbance, and restlessness are important presenting symptoms for this region of COVID-19 disease besides common other symptoms.

According to our study males have a higher infection rate than females 208 (65%) & 112 (35%). [Figure 1A] Also only 18.12% of patients were asymptomatic whereas symptomatic cases were 81.88%. [Figure 2C] This is due to lack of test availability and also tests were made available only to the definite symptomatic patients or those who have radiological or laboratory findings suggestive of SARS-CoV-2 infection. The duration of symptoms had no variation depending on gender and age. [Figure 1 C, Fig. 2F] Male patient’s home isolation and treatment number are higher than the female patients. [Figure 1D] Incase of age group 31 to 40 years are the most affected n = 127/320 and 10 to 20 are the least n = 30/320. [Figure 1E] Cases with or without fevers were high 68.75% and 31.25% compare to Wei-jie Guan
SARS-CoV-2, on the other hand, is a systemic infection with a significant impact on the hematopoietic system and hemostasis, according to the critical review by Terpos et al. done on hematological findings of COVID-19. They have found that COVID-19 disease has prominent manifestations from the hematopoietic system and is often associated with a major blood hypercoagulability. The study indicated that Lymphopenia might be considered as a cardinal finding with prognostic potential. On the other hand, Neutrophil/lymphocyte ratio and peak platelet/lymphocyte ratio may also have prognostic value in determining severe cases. Furthermore, blood hypercoagulability is common among hospitalized COVID-19 patients. Elevated D-dimer levels are consistently reported as well. Thus, the study concluded that in patients with COVID-19 either for hospitalized or not, they are at high risk for venous thromboembolism, and an early and prolonged pharmacological thromboprophylaxis with Low molecular weight heparin (LMWH) is highly recommended.

We had analyzed the on-admission laboratory values of 50 patients with a moderate degree of COVID-19 disease to assess the overall expression. The study revealed an increased level of ESR, CRP, SGPT, Serum Ferritin, Prothrombin time, and D-Dimer. However, the level of Hemoglobin and RBC were decreased and also revealed leukocytosis, neutrophilia, and lymphocytopenia. [Figure 2 C & D] The differential expression of WBC analysis revealed normal mean Neutrophil, Lymphocyte, Monocyte, and Eosinophil count. [Figure 3F] Analysis of biochemical values according to gender revealed differences between males and females in a few parameters. Increased levels of SGPT and S. Ferritin were found among males, and increased levels of D-Dimer were found among females (One in one patient). [Figure 3E] There were no differences in the levels of CRP and prothrombin times between males and females in patients with COVID-19. [Figure 3E] Hemoglobin count was decreased in the case of males (71.42%) than females (36.36%), though RBC count was normal in all the males and decreased among 27.27% of female patients. [Figure 3D] Difference between the decrease hemoglobin count and increased SGPT against male and female patients was found significant. [Figure 3G] All these suggests us to provide more attention towards gender in case of laboratory findings for COVID19 diagnosis and prognosis.

One of our important observations was in delay in diagnosis and therefore treatment from the time of appearance of symptoms, 5.67 ± 3.56 days. [Figure 1C] This is probably explained by delay in publishing test results (2 to 3days from sample collection) unwilling to take tests by patients due to testing and social hazards, and strict indications followed for the PCR test (Fever, breathing difficulty, chest...
discomfort, Chest X-ray findings, and associated hematological findings) by the COVID19 tertiary center doctors due to limited resources.

**Conclusion:**

According to this study COVID19 patient in Bangladesh though has similarity with the presenting symptoms like fever, cough and berating complaints, but symptoms like myalgia, diarrhea, skin rash, headache, Abdominal pain/cramp, nausea, vomiting, restlessness, and a higher temperature of > 100°F have a greater presentation rate and more frequent even as an isolated presentation of SARS-CoV-2 infection than other published studies. Hematological findings like CRP and Prothrombin time were found to increase among all of our study patients. Besides, an increase in Serum ferritin, ESR, SGPT, and D-Dimer along with erythrocytopenia and lymphocytopenia can be important supportive diagnostic criteria. Due to differences in presentations and difficulty in testing, some common symptoms create confusion regarding diagnosis and mislead a SARS-CoV-2 infection like a common viral flue. This might cause morbidity and mortality to COVID19 patients. Moreover, a chest CT is neither affordable for most of the patients nor available in rural healthcare settings in Bangladesh. So, there is a possibility of patients affected by SARS-CoV-2 may remain undiagnosed due to a false negative real-time RT-PCR test or not being sensitive to the real-time RT-PCR test. Thus, if further tests can't be done to confirm the diagnosis such as a chest CT in patients having these common symptoms and hematological manifestations should be treated as COVID-19 patients to narrow the spread of the COVID19 and stop the symptomatic patients from developing severe illness any further. Our study has limitations, namely the small sample size and selection of mild to moderate cases that may affect the study outcome. But we believe the above findings will help to guide physicians and researchers to have a different view and better management of COVID19 disease during this crisis period.

**Abbreviations**

BITID
Bangladesh Institute of Tropical and Infectious Disease.
COVID-19
Coronavirus disease 2019
CDC
Center for disease control and prevention
CRP
C-Reactive Protein
CT
Computed tomography
ESR
Erythrocyte Sedimentation Rate
IgG
Immunoglobulin G
IgM
Immunoglobulin M
IEDCR
Institute of Epidemiology, Disease Control, and Research
LMWH
Low molecular weight heparin
MERS
Middle East respiratory syndrome
RBC
Red Blood Cell
RT PCR
Real-time Polymerase Chain Reaction
SARS-Cov-2
Severe acute respiratory syndrome coronavirus 2
SGPT
Serum glutamic pyruvic transaminase

Declarations

Ethics: Ethical committee approval was taken from Xi’an Jiaotong University.

Consent to participate: Informed written consent was taken in every case. In the case of below 16 years old participants written informed consent was obtained from a parent or guardian.

Competing Interests: None to declare.

Availability of data and materials: The datasets used and/or analyzed during the current study available from the corresponding author on reasonable request.

Funding: Not applicable.

Authors’ contributions:

ATMMC gave the basic research concept, analyzed the data of COVID19 patients, and wrote the manuscript.

MRK wrote the discussion part of the article.

MS and MWC collected the data from the COVID19 patients for analysis of the presenting symptoms.

HMHM collected the laboratory data COVID19 patients.

GD interpreted the data for analysis.
HS gave the concept of research maintained supervision.

All authors have read and approved the manuscript.

Acknowledgment:

The authors are thankful for the kind cooperation of the Chattagram Civil surgeon's office, Chokoria Upazila Health Complex, Chattagram General Hospital, and Department of Gastroenterology-First Affiliated Hospital of Xi’an Jiaotong University.

References

1. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission [PMC free article] [PubMed] [Google Scholar] Evolution of the novel. coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Xu X, Chen P, Wang J, et al. Sci China Life Sci. 2020;63:457–60.[PMC free article] [PubMed] [Google Scholar].

2. Thevarajan I, et al. "Clinical presentation and management of COVID-19." The Medical Journal of Australia, 8 Apr. 2020. https://www.mja.com.au/system/files/2020-04/Preprint%20Thevarajan%20%28Cowie%29%20April%202020.pdf. Accessed 28 May 2020.

3. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. Lu H, Stratton C, Tang Y. J Med Virol. 2020;92:401–2. [PMC free article] [PubMed] [Google Scholar].

4. Centers for Disease Control and Prevention. "Symptoms of Coronavirus Disease 2019poster." Centers for Disease Control and Prevention, 20 May 2020. . Accessed 28 May 2020.

5. Shen M, et al. Recent advances and perspectives of nucleic acid detection for coronavirus. Journal of Pharmaceutical Analysis. 2020;10(2):97–101. doi:10.1016/j.jpha.2020.02.010.

6. Wan Z, et al. A Melting Curve-Based Multiplex RT-qPCR Assay for Simultaneous Detection of Four Human Coronaviruses. Int J Mol Sci. 2016;17(11):1880. doi:10.3390/ijms17111880.

7. Noh JY, et al. Simultaneous detection of severe acute respiratory syndrome, Middle East respiratory syndrome, and related bat coronaviruses by real-time reverse transcription PCR. Arch Virol. 2017;162(6):1617–23. doi:10.1007/s00705-017-3281-9.

8. Tahamtan A. and Abdollah Ardebili. "Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn. 2020;20(5):453–4. doi:10.1080/14737159.2020.1757437.

9. Fang Y, et al. "Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR." Radiology, 2020, 200432, doi:10.1148/radiol.2020200432.

10. Ai T, et al. "Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases." Radiology, 2020, 200642, doi:10.1148/radiol.2020200642.
11. Lovato A. and Cosimo De Filippis. "Clinical Presentation of COVID-19: A Systematic Review Focusing on Upper Airway Symptoms." Ear Nose Throat Journal, 2020, 014556132092076, doi:10.1177/0145561320920762.

12. Guan WJ, et al. "Clinical Characteristics of Coronavirus Disease 2019 in China." The New England Journal of Medicine. 2020;382:1708–20. doi:10.1056/NEJMoa2002032.

13. Song Y, et al. "SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19." Gut, vol. 69, no. 6, 2020, pp. 1143–1144, doi:10.1136/gutjnl-2020-320891.

14. Chan JF, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet. 2020;395(10223):514–23. doi:10.1016/S0140-6736(20)30154-9.

15. Fu B, et al. "SARS-CoV-2-Induced Vomiting as Onset Symptom in a Patient with COVID-19.". Dig Dis Sci. 2020;65(6):1568–70. doi:10.1007/s10620-020-06285-4.

16. Hunt M, Koziatek C. "A Case of COVID-19 Pneumonia in a Young Male with Full Body Rash as a Presenting Symptom." Clinical Practice and Cases in Emergency Medicine, vol. 4, no. 2, 2020, pp. 219–221, doi:10.5811/cpcem.2020.3.47349.

17. Sellevoll HB, et al. "Acute abdomen as an early symptom of COVID-19.". The Journal of the Norwegian Medical Association. 2020. doi:10.4045/tidsskr.20.0262.

18. Terpos E, et al. Hematological findings and complications of COVID -19. Am J Hematol. 2020. doi:10.1002/ajh.25829.

Figures

Figure 1

A- Number of total patients and gender difference of infected in number and percentage. B- Variation in age according to gender and age group. C- Duration of presenting symptoms in general and according to gender. D- Percentage of hospitalized and home isolation-treatment according to gender. E- Number of the COVID19 patients according to age group. Note: 31 to 40 years is the highest and 10 to 20 years is the lowest affected group. F- Duration and grade of fever (<1000F and >1000F) as presenting symptom of COVID19 disease.
Figure 2

Presenting symptoms in percentage (A) and number (B) against the total of COVID19 patients included in this study. C- Symptomatic and asymptomatic cases of COVID19 patients in number. D- Presentation of the number of patients with or without fever against the total number of COVID19 patients included in this study. E- Analysis of cough (Dry and with sputum) as a presenting symptom. F- Age variation according to the gender in the case of Hospitalized and home isolated patients.

Figure 3

Presenting symptoms (in percentage) of male and female symptomatic patients (A & B). C- Differential count of WBC cells, presented as mean ± SD. D & E- Laboratory findings of the hematological changes (in percentage). F- Differential expression of WBC among the patients. G- Significant changes in decrease hemoglobin level and increased SGPT level in Male and Female patients.